Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer.

@article{GonzlezLarriba1997NeoadjuvantTW,
  title={Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer.},
  author={Jos{\'e} Lu{\'i}s Gonz{\'a}lez-Larriba and Iciar Garcia Carbonero and Javier Sastre Valera and Pedro P{\'e}rez Segura and Eduardo Diaz-Rubio},
  journal={Oncology},
  year={1997},
  volume={11 9 Suppl 10},
  pages={90-7}
}
This study compared the activity and toxicity of fluorouracil (5-FU)/ cisplatin with the combination tegafur and uracil (UFT)/cisplatin in the neoadjuvant treatment of locally advanced-stage III or IV (MO)-head and neck cancer. A total of 67 patients were randomly assigned to treatment with cisplatin 100 mg/m2 on day 1 followed by either a continuous infusion of 5-FU 1,000 mg/m2/day on days 2 through 6 (group 1) or oral administration of UFT 300 mg/m2/day on days 2 through 20 (group 2). Both… CONTINUE READING